Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...